top of page


European Commission approves Gevalka ensartinib for ALK-positive advanced lung cancer
The oral ALK inhibitor has secured final EU authorisation for previously untreated and crizotinib-treated ALK-positive advanced non-small cell lung cancer, following evidence of progression-free survival benefit.

nuaxia
1 day ago2 min read


European Commission approves Sanofi's VaxRabeo rabies vaccine for all age groups
The first marketing authorisation for Sanofi's Vero-cell rabies vaccine covers pre-exposure and post-exposure prophylaxis across all ages, supported by comparative immunogenicity and safety data.

nuaxia
1 day ago2 min read


FDA approves Sanofi's Infilbray as first treatment for neurological symptoms of type 3 Gaucher disease
Sanofi's oral glucosylceramide synthase inhibitor becomes the first FDA-approved medicine specifically targeting neurological symptoms of type 3 Gaucher disease, following evidence from a 52-week randomised study.

nuaxia
2 days ago2 min read


FDA approves Regeneron's Livsayis as first quarterly siRNA treatment for generalised myasthenia gravis
Regeneron's first approved siRNA medicine introduces three-monthly subcutaneous treatment for eligible adults with generalised myasthenia gravis, supported by positive Phase III NIMBLE results.

nuaxia
2 days ago1 min read


European Commission approves Amneal's Adcomfo omalizumab biosimilar to Xolair
Amneal has received European Commission approval for Adcomfo, an omalizumab biosimilar to Xolair, covering several allergic and inflammatory conditions and expanding competition in the European biologics market.

nuaxia
3 days ago1 min read


European Commission approves extended Libtayo dosing interval across existing cancer indications
The European Commission has approved a longer dosing interval for Regeneron's Libtayo across its existing authorised cancer indications, offering an alternative administration schedule without expanding the medicine's approved disease indications.

nuaxia
3 days ago2 min read


FDA approves Lembaz as first treatment shown to extend survival in infantile-onset Niemann-Pick disease type C
The FDA has approved Lembaz for patients with infantile-onset Niemann–Pick disease type C, following evidence of extended survival in a rare and progressive neurological disorder.

nuaxia
3 days ago2 min read


European Commission approves Biocon's Pebrilzo as first biosimilar under new tailored clinical approach
Biocon has secured European Commission marketing authorisation for Pebrilzo, its pertuzumab biosimilar, marking what the company describes as the first biosimilar approval under the EMA's tailored clinical approach.

nuaxia
3 days ago1 min read


European Commission approves Sobi and Ionis' Tryngolza for severe hypertriglyceridaemia
The European Commission has approved Tryngolza for adults with severe hypertriglyceridaemia, following Phase III results showing substantial triglyceride reductions and fewer acute pancreatitis events.

nuaxia
3 days ago2 min read


FDA grants accelerated approval to Nuvalent's Nelkarmi for previously treated ALK-positive lung cancer
Nuvalent's Nelkarmi has received FDA accelerated approval for previously treated ALK-positive advanced lung cancer, offering another targeted treatment option for patients whose disease has progressed after earlier therapies.

nuaxia
3 days ago2 min read


FDA approves Teva's Igalmi for at-home treatment of acute agitation in adults with schizophrenia or bipolar disorder
The FDA has expanded the authorised use of Teva's Igalmi sublingual film to at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder and bipolar disorder, introducing a new outpatient treatment setting.

nuaxia
4 days ago2 min read


FDA approves Klygefa gefurulimab for adults with AChR-positive generalised myasthenia gravis
The FDA has approved Klygefa, a weekly subcutaneous complement inhibitor, for adults with acetylcholine receptor antibody-positive generalised myasthenia gravis, adding another targeted treatment option for this autoimmune neuromuscular disorder.

nuaxia
4 days ago2 min read


European Commission approves Revolution Medicines' Rasonque as first broad RAS-targeted therapy for metastatic pancreatic cancer
The European Commission has authorised Revolution Medicines' Rasonque as an oral broad RAS-targeted treatment for previously treated metastatic pancreatic cancer, marking a significant advance in a disease with substantial unmet medical need.

nuaxia
4 days ago2 min read


FDA approves Roche's Gazyva as first specifically authorised treatment for primary membranous nephropathy
The FDA has approved Roche's Gazyva for primary membranous nephropathy, establishing the first specifically authorised treatment for the condition after Phase III evidence demonstrated substantially higher complete proteinuria remission rates than tacrolimus.

nuaxia
4 days ago2 min read


FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche's oral selective oestrogen receptor degrader Wilserdly has received FDA approval alongside everolimus for eligible patients with ESR1-mutated advanced breast cancer, supported by Phase III evidence of reduced disease progression risk.

nuaxia
4 days ago2 min read


CHMP recommends Innovent's Zybrivo sintilimab for first-line non-squamous lung cancer in Europe
The EMA's CHMP has recommended Innovent's Zybrivo, containing sintilimab, for first-line treatment of eligible patients with non-squamous non-small cell lung cancer, advancing the immunotherapy towards a potential European marketing authorisation.

nuaxia
5 days ago2 min read


FDA approves Biocon's Pebrilzo pertuzumab biosimilar for HER2-positive breast cancer
Biocon has secured US FDA approval for Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, expanding its oncology biosimilar portfolio while commercial entry remains subject to a patent settlement allowing launch from the third quarter of 2028.

nuaxia
5 days ago2 min read


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
5 days ago2 min read


UK MHRA approves Incyte's Zynyz for advanced anal cancer as NICE backs NHS access
The UK MHRA has authorised Incyte's Zynyz with carboplatin and paclitaxel for advanced anal cancer, accompanied by a positive NICE access recommendation and Phase III evidence of improved median overall survival.

nuaxia
Nov 132 min read


European Commission expands Oncopeptides' Pepaxti authorisation to third-line multiple myeloma
The European Commission has approved an expansion of Oncopeptides' Pepaxti label into third-line multiple myeloma treatment, broadening eligibility after two prior lines of therapy and removing the previous triple-class refractory requirement.

nuaxia
Nov 132 min read
bottom of page